Therapeutic Asset Ratings

217 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
PROPOFOL Non-small Cell Lung Cancer	Samsung Medical Center	P4	B (57)
Pralsetinib, trans- Non-small Cell Lung Cancer	Fudan University	P3	B (57)
Relatlimab Non-small Cell Lung Cancer	Regeneron Pharmaceuticals	P3	B (56)
Si-B001 Non-small Cell Lung Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P2/3	B (56)
Abiraterone Acetate Non-small Cell Lung Cancer	MacroGenics	P2	CCC (55)
Enzalutamide Non-small Cell Lung Cancer	MacroGenics	P2	CCC (55)
Hydroxychloroquine Non-small Cell Lung Cancer	Abramson Cancer Center at Penn Medicine	P2	CCC (55)
Regorafenib Non-small Cell Lung Cancer	Neonc Technologies, Inc.	P2	CCC (55)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
Bxcl501 Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
CISATRACURIUM ION Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
Desflurane Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
DEXKETOPROFEN Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
DROPERIDOL Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
MAGNESIUM METALLICUM Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
Rocuronium Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
ROPIVACAINE Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
(±)-TRAMADOL Non-small Cell Lung Cancer	University of Crete	P4	CCC (54)
Calderasib Non-small Cell Lung Cancer	Merck Sharp & Dohme LLC	P3	CCC (54)
Shr-A2009 Non-small Cell Lung Cancer	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	CCC (54)
Indocyanine Green Non-small Cell Lung Cancer	St. Joseph's Healthcare Hamilton	P2	CCC (54)
Hyoscine Non-small Cell Lung Cancer	University of Crete	P4	CCC (53)
Pregabalin Non-small Cell Lung Cancer	University of Crete	P4	CCC (53)
Zofran Non-small Cell Lung Cancer	University of Crete	P4	CCC (53)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Non-small Cell Lung Cancer	BOE Technology Group Co., Ltd.	P2	CCC (53)

Showing 51 to 75 of 217 assets

PreviousPage 3 of 9Next